CAPR · Capricor Therapeutics Inc.
The AI's read
An activist just demanded a governance reset, two director nominees, and a formal cash-preservation plan to curb spending and push strategic alternatives. The asks target board control, legal cleanup, and a committee to shift reliance away from the lead asset. Capricor reported $237.9 million cash as of June 30, a $80.2 million drop since year-end 2025, and H1 operating expenses hit $79.7 million with G&A roughly doubling. The stock is already down about 8.1% today, so some downside has been priced but uncertainty remains. We lean bearish because the letter raises clear dilution, execution, and legal-cost risks that often pressure small biotechs. Conviction 84% since the activism cites concrete cash-burn figures and seeks immediate board changes that can be disruptive.